| Literature DB >> 29049290 |
Shau-Huai Fu1, Jyh-You Liu2, Chuan-Ching Huang1, Feng-Ling Lin3, Rong-Sen Yang4, Chun-Han Hou4.
Abstract
Musculoskeletal allografts are now commonly used. To decrease the potential risks of transmission of pathogenic bacteria, fungi, or viruses to the transplant recipients, certain issues regarding the management of patients who receive contaminated allografts need to be addressed. We aimed to clarify the incidence and extent of disease transmission from allografts by analyzing the allografting procedures performed in the bone bank of our hospital over the past 20 years. We retrospectively reviewed the data from our allograft registry center on 3979 allografts that were implanted in 3193 recipients throughout a period of two decades, from July 1991 to June 2011. The source of the allografts, results of all screening tests, dates of harvesting and implantation, and recipients of all allografts were checked. With the help of the Center for Infection Control of our hospital, a strict prospective, hospital-wide, on-site surveillance was conducted, and every patient with healthcare-associated infection was identified. Fisher's exact test was used to compare the infection rate between recipients with sterile allografts and those with contaminated allografts. The overall discard and infection rates were, respectively, 23% and 1.3% in the first decade (1991-2001); and 18.4% and 1.25% in the second decade (2001-2011). The infection rate of contaminated allograft recipients was significantly higher than that of sterile allograft recipients (10% vs. 1.15%, P < 0.01) in the second decade. Both infection and discard rates of our bone bank are comparable with those of international bone banks. Strict allograft processing and adequate prophylactic use of antibiotics are critical to prevent infection and disease transmission in such cases.Entities:
Mesh:
Year: 2017 PMID: 29049290 PMCID: PMC5648119 DOI: 10.1371/journal.pone.0184809
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Source of bone graft.
As the demand for allografts grew rapidly, more bone grafts were harvested during total knee replacement. Other sites for harvesting include the femoral and tibial condyle and proximal humerus.
Pathogens identified in the allograft transplant cases with proven infection (n = 23).
| Case N°. | Sex | Age (years) | Surgery | Wound culture | Swab culture after thawing | |
|---|---|---|---|---|---|---|
| 1 | F | 88 | Revision THR | MRSA | Negative | |
| 2 | M | 68 | Revision THR | MSSA | Negative | |
| 3 | M | 64 | Revision THR | MRSA | Negative | |
| 4 | M | 50 | Tibia open fracture | MSSA | Negative | |
| 5 | F | 70 | PDPIPF | Negative | ||
| 6 | F | 52 | Revision ORIF | MRSA, CoNS | Negative | |
| 7 | F | 12 | PIPF for scoliosis | MRSA | Negative | |
| 8 | F | 55 | Revision THR | CoNS | Negative | |
| 9 | F | 74 | PDPIPF | CoNS | Negative | |
| 10 | M | 86 | PDPIPF | Negative | ||
| 11 | M | 41 | PDPIPF | MRSA | Negative | |
| 12 | F | 82 | Revision THR | |||
| 13 | F | 68 | PDPIPF | MRSA | CoNS | |
| 14 | M | 57 | PDPIPF | CoNS | Negative | |
| 15 | M | 50 | Revision ORIF | Negative | ||
| 16 | M | 56 | Revision THR | MRSA | Negative | |
| 17 | M | 67 | Revision ORIF | MRSA | Negative | |
| 18 | M | 51 | Revision THR | Group B streptococcus | Negative | |
| 19 | M | 71 | Tibia plateau fracture | MSSA, CoNS | Negative | |
| 20 | F | 67 | PDPIPF | MRSA | Negative | |
| 21 | M | 67 | Revision THR | Negative | ||
| 22 | F | 60 | Revision ORIF | Negative | ||
| 23 | M | 24 | Tibia open fracture | Negative | ||
aExtended-spectrum β-lactamase producing Klebsiella pneumoniae
THR: total hip replacement; PDPIPF: posterior decompression, posterior instrumentation, and posterior fusion; ORIF: open reduction and internal fixation; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: Methicillin-sensitive Staphylococcus aureus; CoNS: coagulase-negative staphylococci
Summary of recipients of bone allografts positive for bacterial culture after thawing.
| Recipient | Age (years) / Sex | Procedure | Microorganisms | Infection | Antimicrobial therapy |
|---|---|---|---|---|---|
| 1 | 58 / Male | PDPIPF | CoNS | No | No |
| 2 | 55 / Male | PDPIPF | No | No | |
| 3 | 78 / Male | PDPIPF | CoNS | No | No |
| 4 | 52 / Female | ADAF | No | No | |
| 5 | 73 / Female | PDPIPF | No | No | |
| 6 | 54 / Male | PDPIPF | CoNS | No | No |
| 7 | 73 / Female | PDPIPF | No | No | |
| 8 | 63 / Female | PDPIPF | No | No | |
| 9 | 82 / Female | Revision THR | Yes | Yes | |
| 10 | 68 / Female | PDPIPF | MRSA | Yes | Yes |
| 11 | 76 / Female | Revision ORIF | No | No | |
| 12 | 71 / Male | Revision THR | CoNS | No | No |
| 13 | 87 / Male | PDPIPF | No | No | |
| 14 | 14 / Female | PIPF | CoNS | No | No |
| 15 | 79 / Female | Revision THR | CoNS | No | Yes |
| 16 | 49 / Male | PDPIPF | CoNS | No | No |
| 17 | 46 / Male | Revision THR | Gram-positive rods | No | No |
| 18 | 70 / Female | PDPIPF | Gram-positive rods | No | Yes |
| 19 | 72 / Male | Revision ORIF | Non-fermentative GNB | No | No |
| 20 | 55 / Female | ORIF for tibia plateau fracture | CoNS | No | No |
aBlood: Enterobacter cloacae; Wound: Escherichia coli
bWound: CoNS
cPositive results after-thawing cultures were noted early before discharging the patient, and intravenous antibiotics were administered for 7 days, followed by oral antibiotics for 14 days.
PDPIPF: posterior decompression, posterior instrumentation, and posterior fusion; THR: total hip replacement; ADAF: anterior decompression and anterior fusion; ORIF: open reduction and internal fixation; CoNS: coagulase-negative staphylococci; GNB: gram-negative bacilli